September 19, 2022

Aflibercept 8mg Extended Injection Interval Set to Reduce Treatment Burden for nAMD and DME

Not only is neovascular (wet) age-related macular degeneration (nAMD) one of the leading causes of vision impairment around the world,…

September 15, 2022

Lowering Treatment Burden and Maintaining Vision Gains with Aflibercept

The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy revolutionized the management and treatment of exudative retinal diseases — and…

Discover our fascinating content at issuu